Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Th... ( GAITHERSBURG Md. July 22 /- Sir...)

Sirnaomics Receives SBIR Grant from NIH/NCI for Its Multi-Targeted Lung Cancer siRNA Therapeutics

Date:7/22/2009

GAITHERSBURG, Md., July 22 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has received an SBIR (small business innovation research) grant from National Cancer Institute (NCI), National Institute of Health (NIH), for its novel siRNA therapeutics to treat lung cancer. Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to advancing RNA interference (RNAi) Technology for novel targeted therapeutic development. The company's multi-targeted siRNA therapeutic programs utilizing its nanoparticle-enhanced delivery technologies represent a unique approach for truly realizing the advantages of small interfering RNA (siRNA)-based drugs to treat various critical human diseases. Sirnaomics has successfully attracted grants from NIH and the State of Maryland.

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca, Roche and Takeda have injected billions of dollars into this novel technology and further fueled the enthusiasm for the great promise of siRNA therapeutic development. There are more than a dozen clinical trials currently ongoing for various types of therapeutic applications.

Sirnaomics' mission is to advance RNAi technology by using its proprietary multi-targeted siRNA cocktail design together with the company's nanoparticle-mediated siRNA delivery vehicles in the rapid delivery
'/>"/>

SOURCE Sirnaomics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3
Related biology technology :

1. Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics
2. Sirnaomics and GRL Establish Partnership for the Development of Two Multi-Targeted RNAi Therapeutics Products
3. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
4. TorreyPines Receives Notice of Delisting from Nasdaq Global Market
5. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
6. UCR physicist receives highest honor US government gives young scientists or engineers
7. Professor Fisher receives ASEEs Beer and Johnston Award
8. Mylan Receives FDA Approval for Generic Version of Prostate Cancer Treatment Casodex(R)
9. Unisense FertiliTech A/S Receives CE Mark of Approval for EmbryoScope(TM) Embryo Monitoring System
10. WuXi PharmaTech Receives Award from BASF
11. AEterna Zentaris Receives US$10 Million from Institutional Investors

Post Your Comments:

(Date:5/21/2013)... Bed bugs have become so widespread in the past ... to chemical-based pesticides for help to completely get rid of ... solutions present, the company advised the public to kill ... According to My Cleaning Products, chemical-based pesticides are not as ... shared that the pests have already developed immunity to the ...

(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...

(Date:5/21/2013)... NANONEX CORPORATION, a pioneer and leading company ... successful delivery and installation of a new nanoimprint ... major Japanese manufacturing company. , ... lithography tool that has the ability to process ... types. Based on Nanonex inventions and proprietary technologies, ...

(Date:5/21/2013)... Mississauga, Ontario (PRWEB) May 21, 2013 ... expert scientists of the ITN to design the ... usefulness of two key clinical models used in ... Chamber (EEC) and Nasal Allergen Challenge (NAC) models. ... supported by numerous publications, to date no direct ...

Breaking Biology Technology:New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2 New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3 Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2 Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2 Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2

[0] New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests [0] Revolutionary Science Announces New Automatic and Manual Colony Counting Products [0] Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing [0] Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation.

... FRANCISCO, Feb. 14 BioSpace, the world,s ... announced today the,expansion of its reach to ... by its parent company, onTargetjobs. With the,inclusion ... Internet job boards, BioSpace now offers biotechnology,pharmaceutical, ...

... Pharmaceuticals,Inc. (NASDAQ: ANPI , TSX: ANP), ... today announced unaudited interim and annual,consolidated financial ... ended,December 31, 2007. The unaudited financial results ... as described under the section "Financial,Information"., ...

... Provides Full Year 2008 Revenue Guidance of $350 million ... Symmetry Medical Inc.,(NYSE: SMA ), an independent provider ... medical markets, today reported preliminary,fourth quarter 2007 revenue of ... not be reported at this time., As previously ...

BioSpace.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition Angiotech announces results for the fourth quarter ended December 31, 2007 Symmetry Medical Reports Preliminary Fourth Quarter Revenue

(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...

(Date:5/20/2013)... PAUL (MAY 20, 2013) University of Minnesota Medical ... Minnesota, in partnership with the University,s Brain Tumor Program, ... nerve sheath tumors (MPNST) that allow them to discover ... cancer. , The research was published this week in ... Sleeping Beauty transposon method, researchers in the lab of ...

(Date:5/20/2013)... about the effect of physical education (PE) on child ... that increasing the amount of time that elementary schoolchildren ... , The study represents some of the first evidence ... and is forthcoming in the Journal of Health ... study can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , ...

Breaking Biology News(10 mins):Resistance to last-line antibiotic makes bacteria resistant to immune system 2 Resistance to last-line antibiotic makes bacteria resistant to immune system 3 U of M researchers develop model for better testing, targeting of MPNST 2 Gym class reduces probability of obesity, study finds for first time 2

[0] Resistance to last-line antibiotic makes bacteria resistant to immune system [0] U of M researchers develop model for better testing, targeting of MPNST [0] Gym class reduces probability of obesity, study finds for first time

... ANN ARBOR, Mich.---An international team co-led by scientists from ... the genome with DNA variants that are associated with increased ... A variant is a place on a string of ... people. At most places along the DNA, any two people ...

... , VILLINGEN-SCHWENNINGEN, Germany , June 30 Multicard ... INV) and an identity management systems integrator and solutions provider, announced ... Secure IT kits has been selected under the new electronic identification ... ("Bundesministerium des Innern"). , , ...

... dramatic new real-world evidence supporting the idea that hand ... appears in a new study showing a connection between ... drinking water, and health in households in a developing ... Environmental Science & Technology , a semi-monthly journal. ...

Cached Biology News:New variants found that indicate a predisposition to type 2 diabetes 2 Multicard to Supply Secure IT Kits Under German Federal Government's Electronic ID Program 2 Multicard to Supply Secure IT Kits Under German Federal Government's Electronic ID Program 3

New variants found that indicate a predisposition to type 2 diabetes Multicard to Supply Secure IT Kits Under German Federal Government's Electronic ID Program Real-world proof of hand washing's effectiveness

PEG 8000 is used in the precipitation of phage, isolation of plasmid DNA and the enhancement of blunt-ended ligation reactions....

Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...

... all types of yeast two-hybrid studies, including complex interaction ... Choice of two bait vectors for maximum flexibility ... Triple reporter strain NMY51 ensures ... Complete set of controls: pLexA-p53, pLexA-lamin C ...

PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....

Biology Products:

PEG 8000 Powder from Promega Mouse Matrilin-4 from R&D Systems DUALhybrid kit from Dualsystems Biotech AG PlusOne EDTA, disodium salt from GE Healthcare, formerly Amersham Biosciences